Abstract：
Background: Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma.
Objectives: This study was conducted to evaluate efficacy and safety of interferon (IFN) α-2a combined with phototherapy for early-stage MF.
Methods: Thirteen patients with early-stage MF received subcutaneous injections of IFN α-2a at 3 million IU combined with phototherapy three times per week for 6 months. Treatment efficacy was measured by changes in body surface area (BSA) score and modified severity-weighted assessment tool (mSWAT) score at 1, 3, and 6 months after treatment. Histopathologic examinations of skin lesions were performed before and after treatment.
Results: After 3 months of treatment, all 13 patients achieved a partial response, and BSA and mSWAT scores were significantly lower than those at baseline (p < 0.001). After 6 months, BSA and mSWAT scores were significantly lower than those at baseline (p < 0.001) and after 3 months (p < 0.05). Eleven patients achieved complete remission and two patients achieved a partial response (overall response rate, 100%). Histopathologic examination showed a significant decrease in the number of atypical lymphocytes in both epidermis and dermis. No severe adverse effects occurred.
Conclusion: IFN α-2a in combination with phototherapy may be an effective and safe alternative modality for early-stage MF.
Objectives: This study was conducted to evaluate efficacy and safety of interferon (IFN) α-2a combined with phototherapy for early-stage MF.
Methods: Thirteen patients with early-stage MF received subcutaneous injections of IFN α-2a at 3 million IU combined with phototherapy three times per week for 6 months. Treatment efficacy was measured by changes in body surface area (BSA) score and modified severity-weighted assessment tool (mSWAT) score at 1, 3, and 6 months after treatment. Histopathologic examinations of skin lesions were performed before and after treatment.
Results: After 3 months of treatment, all 13 patients achieved a partial response, and BSA and mSWAT scores were significantly lower than those at baseline (p < 0.001). After 6 months, BSA and mSWAT scores were significantly lower than those at baseline (p < 0.001) and after 3 months (p < 0.05). Eleven patients achieved complete remission and two patients achieved a partial response (overall response rate, 100%). Histopathologic examination showed a significant decrease in the number of atypical lymphocytes in both epidermis and dermis. No severe adverse effects occurred.
Conclusion: IFN α-2a in combination with phototherapy may be an effective and safe alternative modality for early-stage MF.
摘要：
背景：真菌病（MF）是皮肤T细胞淋巴瘤的最常见类型。
目的：本研究旨在评估干扰素（IFN）α-2a联合光疗对早期MF的疗效和安全性。
方法：13例早期MF患者接受3百万IU的IFNα-2a皮下注射联合光疗，每周3次，持续6个月。通过治疗后1、3和6个月的体表面积（BSA）评分和改良的严重程度加权评估工具（mSWAT）评分的变化来衡量治疗效果。治疗前后进行皮肤病变的组织病理学检查。
结果：治疗3个月后，所有13名患者均获得部分缓解，BSA和mSWAT评分显著低于基线(p<0.001)。六个月后,BSA和mSWAT评分显著低于基线(p<0.001)和3个月后(p<0.05)。11例患者达到完全缓解，2例患者达到部分缓解（总体缓解率，100%）。组织病理学检查显示，表皮和真皮中非典型淋巴细胞的数量显着减少。无严重不良反应发生。
结论：IFNα-2a联合光疗可能是治疗早期MF的有效和安全的替代方法。
目的：本研究旨在评估干扰素（IFN）α-2a联合光疗对早期MF的疗效和安全性。
方法：13例早期MF患者接受3百万IU的IFNα-2a皮下注射联合光疗，每周3次，持续6个月。通过治疗后1、3和6个月的体表面积（BSA）评分和改良的严重程度加权评估工具（mSWAT）评分的变化来衡量治疗效果。治疗前后进行皮肤病变的组织病理学检查。
结果：治疗3个月后，所有13名患者均获得部分缓解，BSA和mSWAT评分显著低于基线(p<0.001)。六个月后,BSA和mSWAT评分显著低于基线(p<0.001)和3个月后(p<0.05)。11例患者达到完全缓解，2例患者达到部分缓解（总体缓解率，100%）。组织病理学检查显示，表皮和真皮中非典型淋巴细胞的数量显着减少。无严重不良反应发生。
结论：IFNα-2a联合光疗可能是治疗早期MF的有效和安全的替代方法。
